Incremental Value of NT‐proBNP Over HCM‐AF Score in Risk Stratification for Atrial Fibrillation in Patients With Hypertrophic Cardiomyopathy
Clinical Cardiology · 2026-03 · 49 (3)
DOI: 10.1002/clc.70276 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical Cardiology, online erschienen am 20.03.2026. Verfasst von Yi-Peng Gao und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Ultrasound, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Huazhong, China. Hauptthemen laut MEDLINE: Natriuretic Peptide, Brain, Atrial Fibrillation, Peptide Fragments, Cardiomyopathy, Hypertrophic. Die Arbeit nennt 25 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
HCM‐AF score is a novel risk stratification tool for atrial fibrillation (AF) in hypertrophic cardiomyopathy (HCM). N‐terminal pro‐brain natriuretic peptide (NT‐proBNP) has shown promise in predicting AF. We aim to explore the incremental value of NT‐proBNP over HCM‐AF score.
Methods
In this retrospective cohort study, 778 HCM patients were included. The primary endpoint was new‐onset AF. Spline curve analysis was conducted to identify the cut‐off value of NT‐proBNP. Harrell's C‐index and likelihood ratio test were conducted to explore the incremental value.
Results
After a follow‐up of 3.4 ± 2.3 years, AF occurred in 65 (8.4%) patients. The cut‐off of NT‐proBNP was 240 pg/mL. Incidence rates of AF per 1000 person‐years for the low, intermediate, and high HCM‐AF score groups were 8.7 (95% confidence interval [CI]: 3.5–17.7), 18.0 (95% CI: 7.7–48.8), and 59.6 (95% CI: 27.1–157.1), respectively, with the high HCM‐AF score group significantly higher. For the low and high NT‐proBNP groups, incidence rates were 9.2 (95% CI: 4.6–16.1) and 38.1 (95% CI: 20.3–79.4), respectively. High HCM‐AF score (hazard ratio [HR]: 3.55, 95% CI: 1.33–9.48; p = 0.011) and high NT‐proBNP (HR: 2.49, 95% CI: 1.21–5.10; p = 0.013) are independent predictors for AF. Addition of NT‐proBNP improved models based on HCM‐AF score, with C‐index increasing from 0.709 to 0.768 and likelihood ratio increasing from 33.15 to 51.02.
Conclusion
HCM‐AF score is reliable and robust for Asian HCM patients. NT‐proBNP demonstrated incremental value over HCM‐AF score in the prediction of new‐onset AF in patients with HCM. Future studies are warranted to incorporate HCM‐AF score and NT‐proBNP.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Medical Ultrasound, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Huazhong, China.
Zitieren
APA
Gao, Y. P., Fan, Y. T., Cheng, X. Q., Huang, P. N., Liu, H. Y., Bi, X. J., Sun, J., Zhu, Y., Zhou, W., Liu, Y. N., & Deng, Y. B. (2026). Incremental Value of NT‐proBNP Over HCM‐AF Score in Risk Stratification for Atrial Fibrillation in Patients With Hypertrophic Cardiomyopathy. Clinical Cardiology, 49(3). https://doi.org/10.1002/clc.70276
Vancouver
Gao YP, Fan YT, Cheng XQ, Huang PN, Liu HY, Bi XJ, et al. Incremental Value of NT‐proBNP Over HCM‐AF Score in Risk Stratification for Atrial Fibrillation in Patients With Hypertrophic Cardiomyopathy. Clinical Cardiology. 2026;49(3). doi:10.1002/clc.70276
BibTeX
@article{Gao2026,
author = {Gao, Yi-Peng and Fan, Ya-Ting and Cheng, Xue-Qing and Huang, Pei-Na and Liu, Hong-Yun and Bi, Xiao-Jun and Sun, Jie and Zhu, Ying and Zhou, Wei and Liu, Ya-Ni and Deng, You-Bin},
title = {Incremental Value of NT‐proBNP Over HCM‐AF Score in Risk Stratification for Atrial Fibrillation in Patients With Hypertrophic Cardiomyopathy},
journal = {Clinical Cardiology},
year = {2026},
volume = {49},
number = {3},
doi = {10.1002/clc.70276}
}
EUVIMED